West Pharmaceutical Services (WST) Receives New Coverage from Analysts at Goldman Sachs Group

Equities research analysts at Goldman Sachs Group assumed coverage on shares of West Pharmaceutical Services (NYSE:WST) in a research note issued on Wednesday, Marketbeat Ratings reports. The firm set a “neutral” rating and a $110.00 price target on the medical instruments supplier’s stock. Goldman Sachs Group’s price objective would suggest a potential upside of 8.35% from the company’s current price.

Other research analysts also recently issued reports about the company. Zacks Investment Research downgraded West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Stephens started coverage on West Pharmaceutical Services in a report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price target for the company. Wells Fargo & Co boosted their price target on West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, October 27th. Finally, Bank of America downgraded West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price target for the company. in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $106.80.

Shares of West Pharmaceutical Services (WST) traded up $0.50 during midday trading on Wednesday, reaching $101.52. The company’s stock had a trading volume of 300,690 shares, compared to its average volume of 309,360. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59. The firm has a market capitalization of $7,540.00, a P/E ratio of 40.45, a PEG ratio of 2.15 and a beta of 1.12. West Pharmaceutical Services has a fifty-two week low of $77.97 and a fifty-two week high of $103.36.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.14. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The firm had revenue of $398.20 million during the quarter, compared to the consensus estimate of $386.02 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. The company’s revenue was up 5.7% compared to the same quarter last year. analysts expect that West Pharmaceutical Services will post 2.76 EPS for the current year.

In other news, CFO William J. Federici sold 21,000 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $99.01, for a total value of $2,079,210.00. Following the completion of the sale, the chief financial officer now directly owns 190,493 shares in the company, valued at $18,860,711.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Hillsdale Investment Management Inc. increased its position in shares of West Pharmaceutical Services by 0.7% during the second quarter. Hillsdale Investment Management Inc. now owns 12,080 shares of the medical instruments supplier’s stock worth $1,142,000 after purchasing an additional 80 shares in the last quarter. People s United Financial Inc. boosted its stake in West Pharmaceutical Services by 2.0% during the second quarter. People s United Financial Inc. now owns 15,138 shares of the medical instruments supplier’s stock worth $1,431,000 after buying an additional 295 shares during the last quarter. Suntrust Banks Inc. boosted its stake in West Pharmaceutical Services by 3.4% during the second quarter. Suntrust Banks Inc. now owns 10,849 shares of the medical instruments supplier’s stock worth $1,024,000 after buying an additional 356 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in West Pharmaceutical Services by 1.9% during the second quarter. Ameritas Investment Partners Inc. now owns 22,011 shares of the medical instruments supplier’s stock worth $2,080,000 after buying an additional 415 shares during the last quarter. Finally, Veritable L.P. boosted its stake in West Pharmaceutical Services by 6.2% during the second quarter. Veritable L.P. now owns 7,692 shares of the medical instruments supplier’s stock worth $727,000 after buying an additional 452 shares during the last quarter. Hedge funds and other institutional investors own 93.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/28/west-pharmaceutical-services-wst-receives-new-coverage-from-analysts-at-goldman-sachs-group.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Analyst Recommendations for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply